Navigation Links
Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
Date:12/2/2008

BASKING RIDGE, N.J., Dec. 2 /PRNewswire/ -- Regado Biosciences, Inc., announced today the appointment of Ellen McDonald to the newly created position of Senior Vice President of Business Operations and Chief Business Officer, effective immediately. Ms. McDonald brings to Regado nearly 20 years of experience in the biopharmaceutical industry, with expertise heading business development, operations, portfolio management and marketing. She will report to David J. Mazzo, Ph.D., the Company's President and Chief Executive Officer.

Dr. Mazzo stated, "Ellen has made critical contributions to Regado as a senior consultant, and we are very pleased to announce she is joining the Company's management team. She has a substantial track record in building commercial enterprises and in spearheading the growth of pharmaceutical product portfolios. These capabilities will be invaluable as we further accelerate our lead therapeutic programs." Regado recently completed enrollment in a Phase IIa clinical study (REVERSAL-PCI) of its most advanced therapeutic candidate, the REG1 Anticoagulation System, in patients undergoing elective percutaneous coronary intervention.

Most recently, Ms. McDonald served as Senior Vice President and Chief Business Officer at Aeterna Zentaris, and, prior to that, Senior Vice President, Business Operations at Chugai Pharma USA. At both firms, she had a key role in establishing new directions for the enterprise and facilitating relationships with the financial community. Previously, Ms. McDonald served as Senior Vice President, Cardiovascular Marketing and Medical at Bristol-Myers Squibb, managing a $4.25 billion portfolio of cardiovascular products and a budget of $400 million. She was responsible for leading the growth in sales of Plavix(R), the second-largest-selling drug in the world last year, Pravachol(R) and Avapro(R). Ms. McDonald began her career in the pharmaceutical industry at Johnson & Johnson, where she rose to the leadership of the company's largest pharmaceutical franchise as Vice President, Oncology at Ortho Biotech.

Ms. McDonald is a Director of Cobalis Corporation and a member of the Women's Foreign Policy Group. She earned a Bachelor of Science in General Engineering at the United States Military Academy, West Point, following which she served for five years abroad with the U.S. Army. She also earned a Masters of Business Administration in the Executive Program at Columbia University.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect. Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting. Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.

Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Call for Applications: The Amgen Award for Science Teaching Excellence
2. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
3. Robert L. Brent, MD, PhD, Honored with 2008 Alfred I. duPont Award for Excellence in Childrens Health Care
4. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
5. Early-Bird Registration Ends this Week for 10th Annual Quality Excellence Conference: How Process Improvement Leaders Produce Profits in Recessions
6. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Workforce Alliance Receives U.S. Labor Departments Excellence Award
9. University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence
10. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve
11. Yale Keck Microarray Center Becomes a GeneGo Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
Breaking Biology News(10 mins):